Tag

Wegovy

All articles tagged with #wegovy

health3 days ago•15 min saved

GLP-1 Weight-Loss Drugs Now Used by 11% of Americans

A Gallup poll of 5,065 U.S. adults (May 28–June 5, 2026) finds 11% are currently using GLP-1 weight‑loss drugs (up from 8% in 2025), with 15% having ever tried them and 91% having heard of them; the trend follows FDA approvals for Wegovy (2021) and Zepbound (2023) and coincides with ongoing, but not universal, changes in obesity rates (self‑reported around the mid‑30s). Most users report brand-name drugs, though some use compounded versions; side effects like nausea are possible, while some data suggest reduced cravings, and oral Wegovy (approved 2025) signals more delivery options in the future.

via Gizmodo|

#gallup #glp-1 #health

health5 days ago•6 min saved

Wegovy tablets land in UK pharmacies as private weight‑loss option

Private Wegovy tablets (semaglutide) are now available to buy in UK pharmacies but are not yet offered on the NHS. The daily pill mirrors the injection's weight‑loss effect when combined with a reduced‑calorie diet and increased activity, with eligibility similar to the injection (BMI ≥30 or ≥27 with weight‑related conditions). Start at 1.5 mg daily, titrating up to 25 mg, with prices around £99–£199 per month depending on dose. Take on an empty stomach with up to 120 ml water, 30 minutes before meals, at the same time each day. Side effects include GI issues; serious risks exist. Not for under 18, pregnancy, or breastfeeding. A healthcare consultation is required, and NHS/NICE approval is still pending.

via BBC|

#health #nhs #semaglutide

health21 days ago•23 min saved

Semaglutide drugs may fortify bones in type 2 diabetes, new study suggests

A study of about 59,000 adults with type 2 diabetes found semaglutide (the active ingredient in Ozempic/Wegovy) users had roughly 15% fewer bone fractures than peers on other weight‑loss meds (794 fractures among 26,324 semaglutide users vs 1,045 among 33,555 non‑semaglutide users), despite greater weight loss. The findings, presented at ENDO 2026, suggest a potential bone‑health benefit from semaglutide and underscore monitoring of bone health in weight‑loss therapies for older adults.

via New York Post|

#bone-health #health #ozempic

health26 days ago•2 min saved

GLP-1 Drugs Hint at Cancer Prevention, but Causality Remains Unproven

At a major oncology conference, more than 40 observational studies suggest GLP-1 drugs like Ozempic and Wegovy may lower cancer risk and improve outcomes, potentially by reducing obesity and inflammation. Notable findings include about a 30% reduced breast cancer risk and a roughly 50% drop in lung cancer risk, plus slower progression in several solid tumors. However, because these studies are observational, they cannot prove causality, and randomized trials are needed before using GLP-1s as cancer treatments.

via Futurism|

#cancer #glp-1 #health

health1 month ago•3 min saved

UK approves Wegovy as daily oral weight‑loss pill

Britain’s MHRA has approved Wegovy as an oral, once‑daily tablet for weight loss, a first for the drug, with prescription access opening soon though NHS funding awaits NICE’s decision. The tablet starts at 1.5 mg daily and can rise to 4 mg, 9 mg and 25 mg, taken on an empty stomach and without refrigeration; patients currently using the injection can switch to the 25 mg tablet. Availability is expected through pharmacies, while cost is not yet announced (US pricing had a starting dose around $149/month). Side effects mirror the injectable form and long‑term weight management still requires diet and exercise, with weight potentially returning after stopping.

via BBC|

#health #mhra #novo-nordisk

health1 month ago•4 min saved

Scotland expands NHS weight-loss jab Wegovy for at‑risk patients

Scotland's NHS will offer Wegovy (semaglutide) to overweight patients with cardiovascular risk after approval by the Scottish Medicines Consortium; eligible individuals must have a BMI of 27+ with health risk factors, with about 145,000 Scots potentially eligible. The drug is self-administered at home, may reduce major cardiovascular events beyond weight loss, and can cause side effects like bloating or nausea; rollout follows England's approval and aims to widen access to effective obesity treatments.

via BBC|

#cardiovascular-disease #health #nhs-scotland

business1 month ago•6 min saved

GLP-1 obesity pills head for Medicare era as Novo and Lilly duel on access and convenience

Novo Nordisk and Eli Lilly highlighted the rapid uptake of their GLP-1 obesity pills at a major meeting and outlined plans tied to Medicare’s July rollout, which will cover weight‑loss GLP-1 drugs for about $50 a month. Wegovy prescriptions topped 3 million within roughly five months, while Foundayo is gaining momentum, underscoring a race between the rivals on convenience versus potency and health benefits. Both firms are pushing for broader insurance coverage, studying cost impacts, and advancing pipelines (Lilly’s retatrutide and Novo’s CagriSema) to strengthen their positions beyond current drugs.

via CNBC|

#business #foundayo #glp-1

health1 month ago•50 min saved

My GLP-1 Weight-Loss Journey: Real Benefits, Private Choices

An autoimmune-disease patient shares her first-person experience with GLP-1 weight‑loss drugs (Wegovy), describing rapid energy gains, reduced pain, and improved mobility within weeks, while pushing back against stigma and hype and stressing the importance of private, informed medical decisions and ongoing study of GLP-1s for autoimmune conditions.

via BuzzFeed|

#autoimmune-disease #chronic-pain #glp-1

business1 month ago•2 min saved

Pfizer bets on monthly obesity shot as midstage data show Wegovy-like GI side effects

Pfizer presented midstage results for berobenatide, a monthly GLP-1 obesity drug acquired with Metsera for $10 billion, showing a side-effect profile similar to Novo Nordisk’s Wegovy (average nausea ~38%, vomiting ~23%). The long half-life makes monthly dosing front-loaded, and researchers plan a slower dose ramp in late-stage trials. Weight loss reached up to 12.3% in non-diabetics; analysts expect 20–25% vomiting and see monthly dosing as a potential differentiator from weekly rivals like Wegovy and Lilly’s Zepbound.

via Reuters|

#berobenatide #business #pfizer

health1 month ago•16 min saved

GLP-1 Drugs Hint at Obesity Decline as Prescriptions Rise

New EPIC Research trackers using COSMOS data show GLP-1 prescriptions have risen fourfold since 2021, while obesity within the dataset declined from 42% to 41%, with GLP-1 users seeing a bigger drop (75% to 69%). While not nationally representative, the trend aligns with CDC estimates and other surveys that show rising GLP-1 use. Barriers like side effects, cost, and insurance limit adoption (about 12% of Americans), and cheaper generics abroad could arrive in five years. If adoption continues, obesity could decline further, though long-term effects remain uncertain.

via Gizmodo|

#epic-research #glp-1s #health

health1 month ago•4 min saved

Wegovy May Carry Higher Risk of Rare Eye Stroke, Study Finds

A FAERS-based analysis of over 30 million adverse-event reports suggests Wegovy has the strongest association with ischemic optic neuropathy among semaglutide drugs, with higher signals in men and at higher Wegovy doses. While cases are rare and causation isn’t proven, researchers call for urgent prospective studies as GLP-1 obesity drugs become more widely used.

via ScienceDaily|

#glp-1 #health #ischemic-optic-neuropathy

health1 month ago•9 min saved

New pill could sustain weight loss after GLP-1 injections

Orforglipron, a once-daily small-molecule pill that targets the GLP-1 system and has FDA approval for obesity, may help people keep most of their weight loss after stopping injections like Wegovy or Mounjaro. In a randomized trial, those who switched to orforglipron regained about 26% of lost weight (vs over 50% on placebo) after 52 weeks, with more than two-fifths maintaining at least 80% of their weight loss and improved health markers such as blood sugar, blood pressure, insulin and cholesterol. The pill could be cheaper and easier to store than peptide injections, but it is not yet licensed in the UK for weight loss, and US monthly costs are roughly $149–$299.

via The Conversation|

#glp-1 #health #obesity

health1 month ago•48 min saved

Life After GLP-1s: Real Experiences With Stopping Weight-Loss Drugs

A BuzzFeed News piece compiles Reddit anecdotes about stopping GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) and notes a BMJ meta-analysis finding that people who stop weight loss meds regain weight about four times as fast as those leaving behavioral programs, typically returning to baseline in about 1.7 years. The responses span a spectrum: hunger and food cravings return; some report hair loss or energy dips; many regain weight, but others credit lasting lifestyle changes like mindful eating, calorie tracking, and regular exercise for maintaining weight or easing off gradually. The piece highlights ongoing questions about whether GLP-1s are a temporary boost or a long term tool, and invites more personal experiences.

via BuzzFeed|

#glp-1 #health #mounjaro

business2 months ago•3 min saved

Oral Ozempic and Wegovy Now Eligible for Amazon Same-Day Delivery

Novo Nordisk's oral versions of Ozempic and Wegovy are now available for Amazon same-day delivery, signaling a rapid access expansion after a strong launch that has drawn over a million patients in 16 weeks. The pills—taken daily rather than weekly injections—are expected to boost access to these GLP-1 therapies for diabetes and obesity, with the company citing broader cardiovascular, kidney, and liver benefits and hinting at possible future liver-disease treatments; pricing concessions with the Trump administration aim to broaden affordability, even as short-term effects weigh on the company’s financials.

via New York Post|

#amazon #business #glp-1

business2 months ago•16 min saved

Wegovy-Fueled Q1 Beat Lifts Novo Nordisk's 2026 Outlook

Novo Nordisk beat Q1 estimates on strong Wegovy demand, posting $15.17 billion in revenue and $1.04 in adjusted EPS, and raised its 2026 outlook. The Wegovy pill launch contributed to early sales, with prescriptions surpassing 2 million since launch and more than $2.2 billion in first‑quarter Wegovy pill sales. Management now expects adjusted sales and operating profit to fall 4%–12% for the year, easing fears of a sharp slowdown in the obesity drug market, and the stock moved higher on the report.

via TipRanks|

#business #earnings #novo-nordisk